Live webcasts will be available on the 'Events and Presentations' page in the 'Investors' section of the Company's website at https://investors.deciphera.com/events-presentations. All webcast replays will be archived on the Company's website for 90 days following the presentation.
About
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK is Deciphera's switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in
Contact:
Investor Relations
Deciphera@argotpartners.com
212-600-1902
Media:
david.rosen@argotpartners.com
212-600-1902
(C) 2022 Electronic News Publishing, source